Optimal Measure of PSA Kinetics to Identify Prostate Cancer

Urology

Volumn 71, Issue 3, 2008, Pages 390-394

  Benecchi, Luigi ^a   Pieri, Anna Maria ^a   Destro Pastizzaro, Carmelo ^a   Potenzoni, Michele ^a  

^a Fidenza Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACCELERATION; ADULT; AGED; ARTICLE; CALCULATION; CANCER DIAGNOSIS; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; KINETICS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; TRANSRECTAL ULTRASONOGRAPHY; VELOCITY;

AGED; AGED, 80 AND OVER; BLOOD CHEMICAL ANALYSIS; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 40649091112     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.10.021     Document Type: Article

References (23)

1. Kirbly S.R., Christmas T.J., and Brawer M.K. Prostate Cancer. 2nd edition (2001), Mosby, London, England
2. Zhu H., Kimberly A., Roehl J., et al. Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis. Urology 66 (2005) 547-551
3. Karazanashvili G., and Abrahamsson P.A. Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancer. J Urol 169 (2003) 445-457
4. Benecchi L. Neuro-fuzzy system for prostate cancer diagnosis. Urology 68 (2006) 357-361
5. Carter H.B., Pearson J.D., Metter E.J., et al. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 267 (1992) 2215-2220
6. Roobol M.J., Kranse R., De Koning H.J., et al. Prostate-specific antigen velocity at low prostate-specific antigens levels as screening tool for prostate cancer: results of second screening round of ERSPC. (Rotterdam). Urology 63 (2001) 309-313
7. Komatsu K., Wehner N., and Prestigiacomo A.F. Physiologic (intraindividual) variation of serum prostate-specific antigen in 814 men from a screening population. Urology 47 (1996) 343-346
8. Pound C.R., Partin A.W., Eisenberg M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
9. Patel A., Dorey F., Franklin J., et al. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 158 (1997) 1441-1445
10. D'Amico A., Moul J., Carroll P.R., et al. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specificity mortality following radical prostatectomy or radiation therapy. J Urol 172 (2004) S42-S47
11. Benecchi L. PSA velocity and PSA slope. Prostate Cancer Prostatic Dis 9 (2006) 169-172
12. Choo R., Klotz L., Deboer G., et al. Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate grade, prostate carcinoma. BJU Int 94 (2004) 295-298
13. Hanley J.A., and McNeil B.J. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148 (1983) 839-843
14. Carter H.B., Morrel C.H., Pearson J.D., et al. Estimation of prostatic growth using serial prostate specific antigen measurements in men with and without prostate disease. Cancer Res 52 (1992) 3323-3328
15. Schmid H.P., McNeal J.E., and Stamey T.A. Observation on the doubling time of prostate cancer: the use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 71 (1993) 2031-2040
16. Bidart J.M., Thuillier F., Augereau C., et al. Kinetics of serum tu or marker concentrations and usefulness in clinical monitoring. Clin Chem 45 (1999) 1695-1707
17. Patel A., Dorey F., Franklin J., et al. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 158 (1997) 1441-1445
18. Svatek R.S., Shulman M., Choudhary P.K., et al. Clinical analysis of prostate-specific antigen doubling time calculation methodology. Cancer 106 (2006) 1047-1053
19. Semjonow A., Hamm M., and Rathert P. Half-life of prostate-specific antigen after radical prostatectomy: the decisive predictor of curative treatment?. Eur Urol 21 (1992) 200-205
20. Catalona WL Smith D.S., Ratliff T.L., et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270 (1993) 948-954
21. Spurgeon S.E.F., Mongue-Tchokote S., Collins L., et al. Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy. Urology 69 (2007) 931-935
22. Raaijmakers R., Wildhagen M.F., Ito K., et al. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, Section of Rotterdam. Urology 63 (2004) 316-320
23. Zhang L., Loblaw A., and Klotz L. Modeling prostate specific antigen kinetics in patients on active surveillance. J Urol 176 (2006) 1392-1398